SOMERSET THERAPS LLC
GenericsSOMERSET THERAPS LLC is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease. Key products include POTASSIUM PHOSPHATES.
SOMERSET THERAPS LLC's Key Drugs
SOMERSET THERAPS LLC's core commercial portfolio centers on CISATRACURIUM BESYLATE PRESERVATIVE FREE, SACUBITRIL AND VALSARTAN, POTASSIUM PHOSPHATES, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
SOMERSET THERAPS LLC's Recent FDA Approvals
SOMERSET THERAPS LLC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SOMERSET THERAPS LLC's Therapeutic Areas
SOMERSET THERAPS LLC's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOMERSET THERAPS LLC's Top Competitors
SOMERSET THERAPS LLC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SOMERSET THERAPS LLC Pipeline Snapshot
Active clinical trials for SOMERSET THERAPS LLC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CISATRACURIUM BESYLATE PRESERVATIVE FREE leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2008-03-12
- Latest
- 2026-06-03
- Applications
- 81